R&D Trends

Findings: Treatment-resistant hypertension exerts serious emotional toll on patients

Tuesday, March 5, 2013 04:13 PM

Results from a large, international survey on treatment-resistant hypertension (rHTN) found rHTN has a significant impact on patients' quality of life, having a negative impact on mood, work and interpersonal relationships.

More... »

E.U. to fund $187 million in new research on rare diseases

Tuesday, March 5, 2013 03:56 PM

The European Commission, in honor of Rare Disease Day 2013, has announced $187 million of new funding for 26 research projects on rare diseases. The projects will help improve the lives of some of the 30 million Europeans suffering from a rare disease.

More... »

GNS Healthcare joins Orion Bionetworks to develop predictive models

Monday, March 4, 2013 02:08 PM

GNS Healthcare has joined in the formation of Orion Bionetworks. This unique alliance will work to transform understanding of and accelerate the drug development process for a wide variety of diseases, beginning with multiple sclerosis (MS).

More... »

Top technology gurus join to design mobile phone game to help speed cancer cures

Friday, March 1, 2013 02:30 PM

Cancer Research UK is bringing together its world-leading scientists with technology gurus such as Amazon Web Services, Facebook and Google to design and develop a mobile game to accelerate cures for cancer.

More... »

Parent Project Muscular Dystrophy funds UCLA project

Friday, March 1, 2013 12:46 PM

Parent Project Muscular Dystrophy (PPMD) will provide $100,000 to Dr. Stanley Nelson of the University of California, Los Angeles, to examine the genomes of 40 boys with Duchenne muscular dystrophy who are either very mildly affected or very severely affected.  The goal is to identify changes in genes other than dystrophin that may affect the course of the disease.

More... »

Medicines Patent Pool collaborates with ViiV Healthcare

Friday, March 1, 2013 12:39 PM

The Medicines Patent Pool (MPP) has launched a collaboration with ViiV Healthcare—a joint venture of GlaxoSmithKline, Pfizer and Shionogi—to facilitate greater availability of critically needed medicines for children living with HIV.

More... »

Roche launches process for accessing clinical trial data

Thursday, February 28, 2013 02:24 PM

Basel, Switzerland-based Roche is expanding access to its clinical trial data for third-party researchers. Roche will work with an independent body of recognized experts to evaluate and approve requests to access anonymized patient-level data.

More... »

MJFF surpasses $50M with Brin Wojcicki Challenge

Thursday, February 28, 2013 08:00 AM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) it has completed and surpassed the $50 million Brin Wojcicki Challenge. Longtime foundation supporters Sergey Brin and Anne Wojcicki have matched more than $53 million in capacity-building gifts received by MJFF from January 1, 2011, to December 31, 2012.

More... »

Jazz, Concert partner to develop deuterium-modified sodium oxybate

Wednesday, February 27, 2013 11:54 AM

Jazz Pharmaceuticals, an Irish specialty biopharmaceutical company focused on unmet medical needs, and Concert Pharmaceuticals, a Lexington, Mass.-based clinical stage biotechnology company, have signed an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.   

More... »

LEO Pharma, 4SC Discovery ink exclusive research agreement

Tuesday, February 26, 2013 01:48 PM

LEO Pharma, a global pharmaceutical company specializing in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery with the primary aim of jointly researching, developing and commercializing an oral treatment for inflammatory skin diseases such as psoriasis.

More... »